Barclays Initiates Coverage on Altimmune (NASDAQ:ALT)

Equities researchers at Barclays assumed coverage on shares of Altimmune (NASDAQ:ALT) in a note issued to investors on Tuesday, MarketBeat reports. The firm set an “overweight” rating and a $20.00 price target on the stock. Barclays‘s price target indicates a potential upside of 285.73% from the stock’s previous close.

A number of other research analysts also recently commented on ALT. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research report on Monday, October 20th. Finally, Citizens Jmp reduced their price objective on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Altimmune currently has an average rating of “Moderate Buy” and an average target price of $17.17.

Altimmune Stock Up 1.3%

ALT stock traded up $0.07 during trading hours on Tuesday, reaching $5.19. 2,324,669 shares of the stock were exchanged, compared to its average volume of 6,576,216. The firm’s 50-day moving average is $4.64 and its 200-day moving average is $4.14. Altimmune has a 12 month low of $2.90 and a 12 month high of $7.73. The company has a market cap of $541.00 million, a price-to-earnings ratio of -4.85 and a beta of 0.04. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.08. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%. On average, equities research analysts expect that Altimmune will post -1.35 earnings per share for the current year.

Insider Activity

In other news, Director Jerome Benedict Durso purchased 12,500 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were acquired at an average cost of $4.13 per share, with a total value of $51,625.00. Following the purchase, the director owned 12,500 shares in the company, valued at $51,625. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John Gill acquired 12,500 shares of Altimmune stock in a transaction dated Tuesday, December 23rd. The shares were acquired at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,250. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 30,527 shares of company stock valued at $125,278. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of Altimmune

Several institutional investors have recently made changes to their positions in ALT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Altimmune by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after purchasing an additional 2,241 shares in the last quarter. Concurrent Investment Advisors LLC boosted its stake in shares of Altimmune by 10.4% in the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock worth $96,000 after buying an additional 2,500 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Altimmune by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after acquiring an additional 2,748 shares in the last quarter. Summit Financial Wealth Advisors LLC increased its position in shares of Altimmune by 4.2% during the second quarter. Summit Financial Wealth Advisors LLC now owns 122,988 shares of the company’s stock valued at $476,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC lifted its holdings in Altimmune by 48.1% during the third quarter. Kingswood Wealth Advisors LLC now owns 15,400 shares of the company’s stock worth $58,000 after acquiring an additional 5,000 shares during the period. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.